Skip to content

Polyethylene Glycol (PEG) Bowel Preparation for Prevention of Post-ERCP Pancreatitis (PEP):A prospective, randomized, controlled clinical study.

Polyethylene Glycol (PEG) Bowel Preparation for Prevention of Post-ERCP Pancreatitis (PEP):A prospective, randomized, controlled clinical study.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090142
Enrollment
Unknown
Registered
2024-09-25
Start date
2022-02-09
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post ERCP Pancreatitis

Interventions

Intestinal preparation with PEG group:Participants will ingest one box of PEG dissolved in 1500ml of water at 19:00 on the evening before and at 05:00 on the morning of the ERCP procedure until the bo
No intestinal preparation group:no

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged >18 and <85 years, of any gender. 2. Normal serum amylase levels before ERCP. 3. Willingness to comply with study procedures and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Individuals with severe cardiovascular, renal, or hepatic diseases, such as severe cardiopulmonary or renal insufficiency;2. Pregnant or breastfeeding women;3. Individuals allergic to contrast agents;4. Individuals with pancreatic diseases such as acute pancreatitis, acute exacerbation of chronic pancreatitis, chronic pancreatitis, pancreatic duct dilation, or pancreatic cancer;5. Individuals with active gastrointestinal function;6. Individuals with mental disorders or diseases, partial or complete impairment of consciousness or behavioral abilities, lacking the capacity for independent decision-making;7. Individuals currently participating in other clinical trials or who have participated in other clinical trials within the last 60 days;8. Individuals who refuse to sign the informed consent form;9. Cases deemed unsuitable by the researcher.

Design outcomes

Primary

MeasureTime frame
Amylase 3 hours after ERCP;Amylase 24 hours after ERCP;

Secondary

MeasureTime frame
white blood cell;Aspartate aminotransferase;Alanine aminotransferase;Total bilirubin;C-reactive protein;Procalcitonin;IL-6;IL-8;IL-10;TNF-a;

Countries

China

Contacts

Public ContactLi Yuanyuan

The First Affiliated Hospital of Nanchang University

easily008@163.com+86 150 8352 2327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026